Navigation Links
EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Date:4/22/2008

o develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corpo
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
2. EntreMed Receives Nasdaq Deficiency Notice
3. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
4. EntreMed Announces 2008 Corporate and Clinical Program Priorities
5. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
6. EntreMed to Present at BIO CEO and Investor Conference
7. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
8. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
9. EntreMed Appoints Senior Vice President of Research and Development
10. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... September 30, 2014 SoundConnect, ... collaboration company is dedicated to supporting business communication ... Julie Power, a carrier services ... collaboration solutions stays connected and productive at all ... increased movement of businesses to cloud communications services. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Back in the ... 500 square feet. per employee, which included space for circulation ... then.” says Jeff Howell, partner at Nidea Corporate Real ... in Toronto. “By the year 2000, however, 250 square ... seeing that number come down to 175 to 225 square ...
(Date:9/29/2014)... , Sept. 29, 2014  Ten of ... fields of cartilage repair, regeneration, allograft reconstruction and ... around the world gathered to discuss the future ... Institute of Regenerative Medicine symposium, Cartilage Regeneration: ... Topics included Orthopedic Biosurgery, Minced Juvenile Allograft, and ...
Breaking Biology Technology:The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... LOUIS, Aug. 27 Missouri Coalition for,Lifesaving Cures ... far-,reaching initiative petition filed last week by opponents ... worded and scientifically unsound that it,would exclude Missourians ... syndromes from its definition of "human." In ...
... Drug Royalty LP 2 (DRC) announced,today the ... worldwide,royalty interest in PEG-INTRON for $92.5M. DRC will ... certain royalty recognition levels be met.,PEG-INTRON (peginterferon alpha-2b), ... is marketed worldwide by Schering-Plough Corporation (SGP). ...
... 27 NovaQuest has,made a strategic investment ... specializing in respiratory,disorders. The investment was part ... million) in the Montreal-based company. Last ... partnering group,of Quintiles Transnational, helps TOPIGEN accelerate ...
Cached Biology Technology:New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human 2Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals 2
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
(Date:9/29/2014)... DC September 29, 2014 -- Plants have ... bacteria help the pants extract nutrients and defend ... pathogens from contaminating fruits and vegetables. Now, scientist ... bacteria inside of seeds; thus ensuring that sprouting ... from the University of Notre Dame, presented their ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... of their woody material, could be the key to a ... who add that the approach could also help turn agricultural ... component of woody plant material, is woven in with cellulose ... of wind and microbial attack. However, this protective barrier or ...
... NEW YORK, Dec. 22, 2008 NYU Langone Medical Center ... La Jolla, Calif., have discovered an unexpected cause for the ... of the central nervous system, according to a study published ... new way of thinking about how the human immune system ...
... for humans, Plasmodium falciparum , has been linked ... fairly isolated on the malarial family treeuntil now. A ... Genomics at the American Museum of Natural History reveals ... close evolutionary relationship with P. falciparum and ...
Cached Biology News:Modified plants may yield more biofuel 2Peering inside the skull of a mouse to solve meningitis mystery 2Peering inside the skull of a mouse to solve meningitis mystery 3African thicket rat malaria linked to virulent human form 2
...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... Tecans open platform for clinical diagnostic applications, ... performance in the clinical diagnostic and blood ... barcode reading and sample traceability as standard ... complies with the IVD-Directive* established in the ...
Biology Products: